Full-Time

Senior Medical Director

Oncology Clinical Science

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm focused on R&D

Compensation Overview

$256.2k - $402.6k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Boston, MA, USA

This position is classified as 'hybrid' in accordance with Takeda’s Hybrid and Remote Work policy.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • MD, combined MD/PhD or internationally recognized equivalent plus 7 years of clinical research experience within the pharmaceutical industry, CRO health-related consulting company, or biomedical/clinical experience within academia (or a combination of aforementioned)
  • Previous experience successfully leading a clinical development team/matrix team with responsibility for studies in multiple regions
  • Clinical Training/experience in Malignant Hematology and/or Medical Oncology
  • Therapeutic area knowledge relevant to mechanisms of action of compounds in remit
  • Regional/global Regulatory requirements
  • GCP/ICH
  • Emerging research in designated therapeutic area
Responsibilities
  • Leads the Global Development Team (US, EU, Japan) managing both the US/EU Development Team and the Japan Development team for assigned compounds
  • Directs Development Team strategy and deliverables overseeing the Development Strategy, Clinical Development Plan and Clinical Protocols
  • Responsible for high impact global decisions: monitoring and interpreting data from ongoing internal and external studies
  • Drives all Clinical Science department activities relating to the preparation / approval of Synopses, Protocols and the conduct of clinical studies
  • Oversees medical monitoring activities, assessing issues related to protocol conduct and/or individual subject safety
  • Directs activities involved in interactions with regulatory authorities/agencies and clinical development and key opinion leaders relevant to assigned compounds
  • Responsible for identification and evaluation of potential business development opportunities, conducts due diligence evaluations, and development and negotiation of clinical development plans for potential alliances
  • Interacts directly with research division based on pertinent clinical and development expertise and with TPNA/TPEU to provide knowledge/understanding of market environment in line with status as TGRD scientific content matter expert for assigned compounds
  • Hires, manages, mentors, motivates, empowers, develops and retains staff to support assigned activities
Desired Qualifications
  • NDA/MAA/Submission experience preferred
  • Experience with and demonstrated ability to lead and manage highly trained medical, scientific and technical professionals preferred
  • Superior communication, strategic, interpersonal and negotiating skills
  • Ability to proactively predict issues and solve problems
  • Ability to drive decision-making within a multi-disciplinary, multi-regional, matrix teams
  • Diplomacy and positive influencing abilities across multinational business cultures

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between environmental health and human health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized and environmental risks are managed.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...